Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CHR-2797: Aminopeptidase inhibitor · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| CHR-2797 (tosedostat) | EXPERIMENTAL | oral, once daily administration of CHR-2797 to determine safety \& anti-disease activity. |
| Name | Type | Description |
|---|---|---|
| CHR-2797 (tosedostat): Aminopeptidase inhibitor | DRUG | Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study |
Inclusion Criteria: * Signed, informed consent. * Patients with AML, MDS (subtype RAEB-1 or RAEB-2), or MM whose disease has relapsed or is refractory to front line and/ or salvage therapy; elderly patients (≥ 60 years) with AML, MDS, MM who are not candidates for chemotherapy and for whom other th...
CHR-2797, also known as tosedostat, is an investigational small molecule being studied for the treatment of Acute Myeloid Leukemia (AML). It is an aminopeptidase inhibitor in Phase 1 clinical development. The drug is intended for elderly and/or treatment refractory patients with AML, as well as those with multiple myeloma and myelodysplastic syndrome.
CHR-2797 targets aminopeptidases, which are enzymes involved in protein processing. By inhibiting these enzymes, the drug aims to disrupt cellular processes in cancer cells. This mechanism is being explored as a potential therapeutic approach for Acute Myeloid Leukemia and other hematologic malignancies.
CHR-2797 is being developed by cbdMD, Inc., a company traded under the ticker YCBD. The drug is in Phase 1 clinical development for Acute Myeloid Leukemia. It is a small molecule therapeutic being investigated for its potential anti-disease activity in hematologic cancers.
CHR-2797 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The Phase 1 trial has been completed, having enrolled 57 participants. The study focused on safety and anti-disease activity in patients with Acute Myeloid Leukemia and related conditions.
CHR-2797 has one completed clinical trial, identified as NCT00689000. This Phase 1 study evaluated the safety and anti-disease activity of CHR-2797 (tosedostat) in elderly and/or treatment refractory patients with Acute Myeloid Leukemia and Multiple Myeloma. The trial was conducted in the United Kingdom and enrolled 57 participants.
Yes, CHR-2797 is also known as tosedostat. The clinical trial NCT00689000 refers to the drug as CHR-2797 (tosedostat). This aminopeptidase inhibitor is being investigated for Acute Myeloid Leukemia and other hematologic conditions, and is currently in Phase 1 development.